問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5307Cases

2024-01-01 - 2030-06-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-01-01 - 2032-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

2026-09-11 - 2027-07-19

Phase III

Not yet recruiting
A randomized, multicenter, excipient-controlled, double-blind, phase 3 trial was conducted to evaluate the efficacy and safety of intranasal cenecgerin (recombinant human nerve growth factor [rhNGF]) in adult subjects with non-arterial anterior ischemic optic neuropathy (NAION).

  • Condition/Disease

    Non-arterial anterior ischemic optic neuropathy (NAION)

  • Test Drug

    Cenegermin

Participate Sites
2Sites

Not yet recruiting2Sites

2024-01-01 - 2027-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2040-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-01-16 - 2026-06-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-01-26 - 2029-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-02-01 - 2038-01-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2026-10-01 - 2030-03-31

Phase II/III

Not yet recruiting
A sequential phase 2/3 trial, initially a single-arm, open-label trial in adults, followed by a randomized, placebo-controlled, double-blind, multicenter trial in adults and adolescents, will evaluate the efficacy and safety of Pegcetacoplan in treating focal segmental glomerulosclerosis.

  • Condition/Disease

    Focal segmental glomerulosclerosis

  • Test Drug

    Pegcetacoplan (APL-2) 1080 mg in 20 mL (54 mg/mL) or Placebo solution Pegcetacoplan (APL-2) 1080 mg in 20mL (54mg/ml) solution

Participate Sites
5Sites

Not yet recruiting5Sites

2024-02-01 - 2026-07-27

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

1 5 6 7 8 9 531
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB